The discovery and development of binimetinib for the treatment of melanoma

References

• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851–857.
   PubMed Web of Science ®Google Scholar
• Arnold M, de Vries E, Whiteman DC, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018;143(6):1305–1314.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953-2008–are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385–400.
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of Incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161–1171.
   PubMed Web of Science ®Google Scholar
• Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60.
   PubMed Web of Science ®Google Scholar
• Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040–2059.
   PubMed Web of Science ®Google Scholar
• Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer–the role of sunlight. Adv Exp Med Biol. 2008;624:89–103.
   PubMed Web of Science ®Google Scholar
• Matthews NH, Li W-Q, Qureshi AA, et al. Epidemiology of melanoma. In: Ward W, Farma J, editors. Cutaneous melanoma: etiology and therapy. Brisbane (AU): Codon Publications; 2017. p. 3–22.
   Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161(7):1681–1696.
   PubMed Web of Science ®Google Scholar
• Torii S, Yamamoto T, Tsuchiya Y, et al. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 2006;97(8):697–702.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396–405.
   PubMed Web of Science ®Google Scholar
• Rabbie R, Ferguson P, Molina-Aguilar C, et al. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247(5):539–551.
   PubMed Web of Science ®Google Scholar
• Tsao H, Chin L, Garraway LA, et al. Melanoma: from mutations to medicine. Genes Dev. 2012;26(11):1131–1155.
   PubMed Web of Science ®Google Scholar
• Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–183.
   PubMed Web of Science ®Google Scholar
• Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81(2):807–869.
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004;64(7):2338–2342.
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Arozarena I. The Complexity of the ERK/MAP-Kinase Pathway and the treatment of melanoma skin cancer. Front Cell Dev Biol. 2016;4:33.
   PubMed Web of Science ®Google Scholar
• Pheneger J, Wallace E, Marlow A. Characterisation of ARRY-438162, a potent MEK inhibitor in combination with methotrexate or ibuprofen in in vivo models of arthritis. Abstract published from the American College of Rheumatology 2006 Scientific Meeting. [cited 2020 Feb 1]. Available from: https://acr.confex.com/acr/2006/webprogram/Paper5558.html
   Google Scholar
• Lee PA, Wallace E, Marlow A, et al. Abstract 2515: preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor. Cancer Res. 2010;70(8 Supplement):2515.
   Google Scholar
• Highlights of Prescribing Information. MEKTOVI® (binimetinib) tablets. FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf
   Google Scholar
• Bendell JC, Papadopoulos K, Jones SF, et al. Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Mol Cancer Ther. 2011;10(11 Supplement):B243–B243.
   Google Scholar
• Bendell JC, Javle M, Bekaii-Saab TS, et al., A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017;116(5):575–583.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• US Department of Health Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009; 4(3).
   Google Scholar
• Kefford R, Miller WH, Tan DS-W, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J clin oncol. 2013;31(15_suppl):9029.
   Web of Science ®Google Scholar
• Sullivan RJ, Weber JS, Patel SP, et al., A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J clin oncol. 2015;33(15_suppl):9007.
   Web of Science ®Google Scholar
• Ascierto PA, Bechter O, Wolter P, et al. A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. J clin oncol. 2017;35(15_suppl):9518.
   Google Scholar
• Sosman JA, Kittaneh M, Lolkema MPJK, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J clin oncol. 2014;32(15_suppl):9009.
   Web of Science ®Google Scholar
• Schuler MH, Ascierto PA, Vos FYFLD, et al. Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: safety, efficacy, and recommended phase 2 dose (RP2D). J clin oncol. 2017;35(15_suppl):9519.
   Google Scholar
• Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435–445.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al., Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–1327.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
   PubMed Web of Science ®Google Scholar
• Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4(1):61–68.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Flaherty KT. New strategies in melanoma: entering the era of combinatorial therapy. Clin Cancer Res. 2015;21(11):2424–2435.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N Engl J Med. 2014;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK inhibitors Dabrafenib and Trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639–1651.
   PubMed Web of Science ®Google Scholar
• Drago JZ, Lawrence D, Livingstone E, et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Res. 2019;29(1):65–69.
   PubMed Web of Science ®Google Scholar
• Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.
   PubMed Web of Science ®Google Scholar
• Mektovi Prices, Coupons and Patient Assistance Programs. [cited 2019 Apr 10]. Available from: https://www.drugs.com/price-guide/mektovi
   Google Scholar
• Curl P, Vujic I, van ‘T Veer LJ, et al. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014;9(9):e107255.
   PubMed Web of Science ®Google Scholar